Skip to main content
Zelluna ASA logo

Zelluna ASA — Investor Relations & Filings

Ticker · ULTI ISIN · NO0010851603 LEI · 254900B4VALJZR9TL744 OL Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2021-05-11 Interim / Quarterly Rep…
Country NO Norway
Listing OL ULTI

About Zelluna ASA

https://www.zelluna.com/

Zelluna ASA is a cell therapy company pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company's proprietary TCR-NK platform is designed to combine the high-precision targeting of TCRs with the potent, innate anti-tumor activity of NK cells. This approach aims to overcome the challenges associated with treating solid tumors. Zelluna is focused on creating a new generation of allogeneic, "off-the-shelf" cell therapies. The mission is to deliver transformative and potentially curative treatments for patients with advanced solid cancers, addressing a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Ultimovacs ASA: First quarter 2021 result presentation
Interim / Quarterly Report Classification · 100% confidence The document is titled 'FIRST QUARTER 2021 REPORT' and contains detailed operational updates, clinical trial progress, and financial statements (including a 'Key financials' table with Q1-21 data). It is a comprehensive report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q1 2021
2021-05-11 English
Ultimovacs ASA: First quarter 2021 result presentation
Investor Presentation Classification · 95% confidence The document is a 'First quarter 2021 presentation' from Ultimovacs. It contains detailed operational updates, clinical trial progress, and financial tables (Key financials per Q1-2021). While it is a presentation, it provides substantive financial data and analysis for a specific quarterly period, fitting the definition of an Investor Presentation (IP) which often serves as the primary communication vehicle for quarterly results in biotech firms, or potentially an Interim Report (IR). Given the structure is a slide deck focusing on strategy, pipeline, and financial highlights, 'Investor Presentation' is the most accurate classification. Q1 2021
2021-05-11 English
Ultimovacs ASA: First quarter 2021 result presentation
Earnings Release Classification · 95% confidence The document is titled "Ultimovacs ASA: First quarter 2021 result presentation" and explicitly announces the release of the first quarter 2021 results, followed by key highlights and details about ongoing clinical trials and financial metrics for Q1-21. This content structure—announcing results for a specific interim period (Q1) with management commentary and key figures—is characteristic of an Earnings Release (ER). Although it mentions a presentation, the core content provided is the summary of the results, not just the announcement of the presentation itself, which would lean towards RPA. Since it provides the actual highlights and financial summary for the period, ER is the most appropriate classification over a simple RPA or IR (which is usually more comprehensive). Q1 2021
2021-05-11 English
Ultimovacs to discuss ASCO UV1 Phase I Data in Webcast and Investors Meetings
Investor Presentation Classification · 95% confidence The document is a press release from Ultimovacs announcing that its management team will discuss data from an ASCO abstract (Phase I trial results for UV1) during a series of investor events, including a live corporate webcast, podcast appearances, and industry forums, scheduled throughout May and June 2021. This is not the full report (10-K, IR), nor is it the actual presentation material (IP). It is an announcement about upcoming investor engagement and the availability of an abstract/poster presentation. Since the core purpose is to announce investor meetings and the release of preliminary data discussion points, it fits best as an Investor Presentation (IP) announcement or, more generally, a Report Publication Announcement (RPA) if it were announcing the release of a formal report. However, given the focus on discussing data at investor events (webcasts, forums), it strongly relates to investor communication surrounding clinical data. Since it is an announcement *about* upcoming discussions and the release of an abstract, and not the presentation itself, the closest fit among the options that deal with investor communication about results/data is Investor Presentation (IP) or Report Publication Announcement (RPA). Given the short length (3582 chars) and the focus on announcing when management will discuss data and when the abstract will be available, RPA is a strong candidate as it announces the publication/discussion of data. However, the content is heavily focused on detailing the schedule of investor meetings where management will present/discuss the findings, which aligns closely with the context of an Investor Presentation (IP) being discussed or released. Since it is an announcement *about* upcoming investor events where data will be discussed, and not the formal presentation itself, RPA (Report Publication Announcement) is the most appropriate category for this type of press release announcing the schedule for discussing data/abstracts, adhering to the 'MENU VS MEAL' rule.
2021-05-10 English
Ultimovacs ASA: Invitation to first quarter 2021 results webcast presentation
Report Publication Announcement Classification · 98% confidence The document is titled 'Ultimovacs ASA: Invitation to first quarter 2021 results webcast presentation'. It explicitly invites stakeholders to a webcast presentation of the first quarter 2021 results, scheduled for May 11, 2021. It states that the 'report and presentation will be available on the company website from 08:00 CET the same day.' Since the document itself is an invitation/announcement about the upcoming release of the results and presentation, and not the results themselves (which would likely be an ER or IR), it fits the definition of a Report Publication Announcement (RPA). The document length is very short (1087 chars), supporting the 'MENU VS MEAL' rule.
2021-05-05 English
Ultimovacs Announces UV1 Data Presentation at Upcoming 2021 ASCO Annual Meeting
Legal Proceedings Report Classification · 99% confidence The document is a press release titled "Ultimovacs Announces UV1 Data Presentation at Upcoming 2021 ASCO Annual Meeting." It details the acceptance of an abstract for a poster presentation at a medical conference (ASCO 2021) and provides details about the presentation schedule and the content of the study (Phase I trial for UV1 vaccine). This type of announcement, which informs the public about the presentation of clinical trial data or research findings at an industry event, does not fit neatly into the standard financial filing categories (like 10-K, ER, IR). Since it is an announcement about research/clinical progress rather than a formal financial report, a dividend notice, or a management change, the most appropriate classification is the general regulatory/announcement fallback category, RNS (Regulatory Filings), as it is a material corporate announcement.
2021-04-28 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.